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ABSTRACT 
Objective: The purpose of this work was to develop and validate a novel HPLC-UV method using triethylamine (TEA) as a volatile buffer for 
simultaneous determination of amlodipine besylate (AML) and atorvastatin calcium (ATV).  
Methods: System suitability, linearity, limit of detection (LOD), limit of quantification (LOQ), selectivity, accuracy, and precision was validated using 
Hitachi L-2000 system with detector: DAD L-2455 at a detected wavelength of 245 nm. Stationary phase: Phenomenex Luna RP-C18 (250 mm x 4.6 
mm, 5 µm) and mobile phase: acetonitrile-methanol-TEA pH 4.0 (ratio 52:18:30 v/v/v) were used. Samples’ volume of 20 µl was run at room 
temperature with the flow rate at 1 ml/min.  
Results: The linearity demonstrated good correlation in the concentration range at 2-40 ppm and 4-80 ppm for AML and ATV, respectively. The 
method was repeatable with relative standard deviation (RSD) of the intermediate precision test less than 1%. The recovery rate was 100.03% and 
99.58% for AML and ATV, respectively. The method was also validated for dissolution studies with excellent compatibility.  
Conclusion: A new, simple and easy HPLC-UV method was successfully developed and validated for the determination of AML and ATV in both 
quantification test and dissolution test. 
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INTRODUCTION 
Recently, cardiovascular diseases (CVDs) have been the number one 
cause of death in the world, especially in low-and-middle-income 
countries. In 2012, approximately 17.5 million people died from 
these illnesses, attributing 31% of deaths globally [1]. Among many 
risk factors, namely, unhealthy diet, tobacco smoke, physical 
inactivity, and alcohol abuse, that can contribute to the onset of 
CVDs, hypertension and hyperlipidemia are considered the most 
frequent and important ones [1].  
AML (fig. 1) is the besylate conjugated form of amlodipine, a 
dihydropyridine-type calcium channel blocker that can widen the 
blood vessel, hence, lower the blood pressure. On the other hand, 
ATV (fig. 2) is the calcium salt of a lipid lowering agent which works 
by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase, an 
enzyme that plays a key role in the cholesterol synthesis pathway. 
The combination of AML and ATV have been proved a significant 

































Some simultaneous determination methods for this combination 
have been published, utilizing the UV-Vis spectrophotometry [5, 6], 
the HPLC-UV [7-9], the HPLC-MS/MS [10, 11], or the capillary 
electrophoresis [12]. No outstanding methods have been recognized 
so far; since UV-Vis spectrophotometry method has low sensitivity 
and selectivity; HPLC-MS/MS method is the most expensive one, and 
therefore, used only in determining drug concentration in human 
plasma. The suitable method for measuring both AML and ATV in 
pharmaceutical dosage forms is HPLC-UV.  
However, to the best of our knowledge, the mobile phases of 
previously published methods contained nonvolatile buffers, mainly 
phosphate salts (table 1). These salts can block the capillaries and 
the column, hence, increase the system pressure, reduce the 
method’s robustness, and consume longer column cleaning time 
[13]. Also, no methods reported so far have been applied for the 
simultaneous determination of AML and ATV in tablet dissolution 
profiles. 
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Table 1: Summary of HPLC-UV methods for simultaneous determination of AML and ATV. MeOH: Methanol; ACN: Acetonitrile 
S. No. Sample solvent Stationary phase Mobile phase Ref 
1 MeOH, water, mobile phase PerfectSil Target ODS-3 
(250 mm x 4.6 mm, 5 µm) 
ACN-NaH2PO4 [7]  pH 4.5 (55:45) 
2 Mobile phase Grace Smart RP C-18 
(250 mm x 4.6 mm, 5 µm) 
ACN-MeOH-H3PO4 [8]  (43:4:53) 
3 Mobile phase RP C-18 Kromasil 
(250 mm x 4.6 mm, 5 µm) 
ACN-NH4H2PO4 [9] (40:60) 
Therefore, in this study, we aimed to develop a new HPLC-UV method, using a volatile buffer, for simultaneous determination of AML and ATV in 
both tablet quantification and dissolution profiles. 
 
MATERIALS AND METHODS 
Chemicals and reagents 
AML and ATV references were purchased at Institute of Drug Quality 
Control, Ho Chi Minh City, Vietnam, with purity of 100.34% and 
94.25%, respectively. AML and ATV ingredients, USP grade, were 
acquired from India. Amdepin Duo® film coated tablets (AML 5 mg, 
ATV 10 mg) of Cadila, India, register number VN-4367-07, batch 
number ADE2004, were obtained from Kim Loi drugstore, Can Tho, 
Vietnam. Test tablets were manufactured in Department of 
Pharmaceutical Technology, Can Tho University of Medicine and 
Pharmacy, Vietnam with pharmaceutical grade ingredients (i.e. 
starch, povidone K30, talc, magnesium stearate, avicel PH-102, 
CaCO3, ethanol 50%) imported from China. Acetonitrile (ACN), 
methanol (MeOH), glacial acetic acid, formic acid, orthophosphoric 
acid, TEA, NaOH, KH2PO4 were purchased from Merck, Germany. All 
reagents used were qualified as analytical grade, except for ACN, 
MeOH and double distilled water with HPLC grade. 
HPLC instrumentation and conditions 
The HPLC system used was Hitachi L-2000, detector: DAD L-
2455, stationary phase was Phenomenex Luna RP-C18 (250 mm 
x 4.6 mm, 5 µm). Samples were run at the volume of 20 µl with 
optimized mobile phase consisted of ACN-MeOH-TEA buffer pH 
4.0 (ratio 52:18:30 v/v/v) at room temperature with the flow 
rate at 1 ml/min. The eluent was detected at the wavelength of 
245 nm. 
Method validation 
Method development and validation were based on International 
Council for Harmonisation (ICH) guideline [14, 15] with the 
parameters, namely system suitability, linearity, LOD, LOQ, 
selectivity, accuracy, and precision for both quantification study and 
dissolution study. 
Tablet formulation 
Three new tablet formulas contained both AML and ATV were 
manufactured by wet granulation method [16]. Briefly, active 
ingredients, starch, and avicel PH-102 were mixed for 15 min. 
Approximately 140 ml ethanol 50% solution of povidone K30 was 
added to the mixture and granulated with Erweka AR-402 (Germany) 
machine. The granules were mixed with talc and magnesium stearate 
for 15 min before tableting with Rimek Mini Press-I (India), die 
diameter of 7 mm, to get 150 mg tablet with a hardness of 50-60 N. 
Dissolution study 
Amdepin Duo® tablet and three formulations were tested dissolution 
profiles with Pharmatest PT-DT8S Tester (Germany) using paddle 
apparatus, 75 rpm/min, in 900 ml of phosphate buffer pH 6.8, at 37 o
10 mg AML and 20 mg ATV references were accurately weighed and 
dissolved in 100 ml MeOH. After 10 minute sonication, the solution 
was diluted to 200 ml with water. This solution was further diluted 
ten times to get the final concentration of AML and ATV at 5 ppm 
and 10 ppm, respectively. 
Sample solution preparation for quantification 
Twenty Amdepin Duo
C. 
10 ml of each sample was withdrawn at each time interval of 5, 10, 15, 
and 30 min, filtered, and determined the drug concentration based on 
validated method. All tests were done in triplicate. 
Standard solution preparation for quantification 
® tablets or test formulations were weighed, 
crushed and mixed. An accuracy amount of powder equal to the 
weight of one tablet was dissolved in 50 ml MeOH and sonicated for 
10 min. The solution was diluted with 50 ml of water and filtered. 
This solution was then further diluted ten times with water and 
filtered through a Millipore membrane (0.45 µm) (Merck, Germany) 
to get the concentration of AML and ATV at approximately 5 ppm 
and 10 ppm, respectively. 
RESULTS AND DISCUSSION 
Hypertension and hyperlipidemia are the most popular and 
dangerous risk factors of CVDs [1]. AML and ATV combination (i.e. 
Amdepin Duo®) can reduce these risks significantly. However, to the 
best of our knowledge, no perfect method to determine both AML 
and ATV in both quantification test and dissolution profiles. Hence, 
our newly developed method may be considered for these purposes. 
Method optimization 
Optimal conditions for a suitable method can be characterized as 
follows: short retention time, sharp peak, asymmetric factor in the 
range of 0.8-1.2. Since the pKa
Five different concentrations of standard AML and ATV, ranging from 2 
to 40 ppm and from 4 to 80 ppm, respectively, was used to determine 
the calibration curves. Each concentration was measured three times, 
and average values were obtained. The result is illustrated in fig. 4. 
Calculated based on ICH guideline [14, 15], the LOD and LOQ of AML is 
0.3169 and 1.0563; of ATV is 0.3572 and 1.1907, respectively. The 
linearity was confirmed, the calibration curves of both AML and ATV had 
a coefficient of determination (R
 of AML and ATV are 8.6 and 4.5, 
respectively, the suitable buffer pH should be from 3 to 6. The UV 
spectrum of AML showed absorption peaks at 238 and 361 nm. On the 
other hand, ATV has maximum absorption at the wavelength of 245 
nm. Hence, the wavelength of 245 nm was used to simultaneous 
determine both substances because not only it can yield the best 
chromatography results, but also reduces the noise from HPLC mobile 
phase namely ACN, MeOH [13]. In addition, as mentioned earlier in the 
introduction part, the use of nonvolatile buffers is not preferable [13]. 
The volatile buffer TEA can eradicate this problem. After several 
preliminary studies, we chose the optimal chromate-graphic 
conditions as demonstrated in the materials and methods section. 
Method validation 
System suitability 
Six replicative standard and test samples were injected into the 
system. Results are shown in table 2. All values had RSD<2%, the 
resolution between peaks were larger than 1.5, asymmetric factors 
were in the range of 0.8-1.2, and theoretical plates were higher than 
1500. Hence, the method had system suitability. 
Specificity 
Five samples included standard sample, test sample, blank sample, 
standard and mixture test sample, and mobile phase sample, were 
measured and the chromatograms were overlaid (fig. 3). Specificity 
was validated with no interference from other substances, and test 
sample demonstrated similar retention time with the references. 
Linearity 
2) of an acceptable value of 0.9998. 
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Table 2: System suitability of method on standard and test samples. sAML: standard AML; sATV: standard ATV; 𝐗𝐗�: mean; RSD%: relative 
standard deviation; tR:  
 
retention time; S: peak area; Rs: resolution; N: theoretical plates; As: asymmetric factor; K’: retention factor 



























































Fig. 3: Overlaid chromatogram of specificity validated samples. (1): test sample, (2): standard and test mixture sample, (3): standard 
sample, (4): blank sample, (5): mobile phase sample 
 
 
Fig. 4: Calibration curves in linearity study of AML and ATV, in a 




The intermediate precision test was performed. Twelve test samples 
were run consecutively. Six samples were injected into HPLC Hitachi 
L-2000, detector DAD L-2455, column Phenomenex Luna RP-C18 
(250 mm x 4.6 mm, 5 μm) at Can Tho University of Medicine and 
Pharmacy, Vietnam (condition 1). Another six were injected into 
HPLC Hitachi L-2000, detector DAD L-2455, column Restek Pinnacle 
II C18 (250 mm x 4.6 mm, 5μm) at the Can Tho Institute of Drug 
Quality Control, Vietnam (condition 2). Data are shown in table 3. 
Intermediate precision in two different locations at two different 
times shown RSD<1%, indicating good repeatability. 
Accuracy 
Standard solution of AML and ATV with a concentration of 80%, 100%, 
and 120% compared to the estimated amount of AML and ATV was 
added to the test samples. The accuracy was determined by the average 
recovery rate of the samples. Results are demonstrated in table 4. The 
satisfied recovery rate at 100.03% and 99.58% of AML and ATV, 
respectively, demonstrate excellent accuracy. Overall, our method was 
validated successfully with acceptable parameters according to ICH. 
Dissolution test 
The dissolution tests were done with three formulations (A, B, C) 
along with the reference drug Amdepin Duo®
 
 after re-validating the 
method with buffer pH 6.8 as a sample solvent. The profiles are 
illustrated in fig. 5. 
Table 3: Intermediate precision test at two different places and times 
Sample Intermediate precision 
AML (%) ATV (%) 
Condition 1 Condition 2 Condition 1 Condition 2 
1 100.8 99.2 99.8 98.1 
2 102.0 99.0 100.5 97.2 
3 99.4 99.6 98.8 97.7 
4 100.4 100.0 98.8 97.6 
5 100.8 98.8 99.8 97.3 
6 99.4 99.0 98.5 97.1 
Mean 100.4 99.2 99.4 97.5 
RSD% 1.04 0.47 0.78 0.39 
Intermediate precision 99.8 98.5 
RSD% 0.75 0.58 
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Table 4: Experimental results for the accuracy test for AML and ATV 
Substance Added amount Found amount (ppm) Recovery (%) Average recovery (%) 
% ppm 
AML 80 4.09 4.05 99.02 100.03 
100 5.12 5.20 101.56 
120 6.14 6.11 99.51 
ATV 80 7.58 7.47 98.55 99.58 
100 9.47 9.52 100.53 
120 11.37 11.33 99.65 
 
 
Fig. 5: Dissolution profiles of AML (A) and ATV (B) in 4 formulations, namely A, B, C, and Amdepin Duo®
 
The method has a broad range of concentration value from 40% to 
800% of quantification value (i.e. 2-40 ppm for AML and 4-80 ppm 
for ATV). Therefore, it is suitable for determining the dissolution 
profiles of pharmaceutical dosage forms. To accomplish this, we 
validated the method again in sample solvent at pH 6.8 (data not 
shown). Hence, the method can be used for dissolution purpose. 
CONCLUSION 
In this study, we developed and validated a novel, simple, and 
flexible HPLC-UV method using volatile buffer triethylamine for 
simultaneous determination of amlodipine besylate and atorvastatin 
calcium. Furthermore, this approach can be applied for both 
quantification and dissolution profiles. 
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